December 2nd 2024
If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Derms Reflect on Cosmetics Impact
February 1st 2003The image of dermatology as a medical profession has undergone a variety of changes over the decades. In the 1800s and the early part of the 20th century, dermatologists were the physicians to go to for venereal diseases, as well as diseases of the skin, so their place as a medical necessity was secure.
Innovate, integrate, and treat
January 1st 2003Las Vegas - Much of what is new in dermatologic therapy represents off-label use of marketed drugs, but clinicians should not let that fact necessarily deter them from prescribing what may be very safe and effective therapy, said Stephen Stone, M.D., at the Fall Clinical Dermatology Conference.
Psychology of psoriasis keys compliance
January 1st 2003New York - For treatment of localized psoriasis, breaking down the barriers to compliance can begin with something as simple as the human touch, according to Steven R. Feldman, M.D., Ph.D., director, Psoriasis Treatment Center, Wake Forest University School of Medicine, Winston-Salem, N.C.
Management beyond corticosteriods starts with assessing risk to skin, reducing sun exposure
January 1st 2003Paris - Treatment for dermatomyositis (DM) begins with sun avoidance and sun-protective measures, Jeffrey P. Callen, M.D., said at the World Congress of Dermatology. "The first line of therapy is to recognize that the patient is photosensitive."
Is Parental Consent Valid for Minor Children?
December 15th 2002Anew oral retinoid has been FDA cleared for the treatment of psoriasis. It has been shown to be safer than all previously available retinoids. Dr. Doe learned that this medication has been used safely in Europe for the prevention of acne in pre-adolescent teenagers. He has a large adolescent practice and is excited about using this medication on his young patients. Recognizing that the drug does not have FDA clearance for his intended use, he asks parents of prospective patients to sign a consent form allowing him to use this potentially miraculous drug on their children. Is the consent of the parent valid?